Key result
Intra-arterial verapamil attenuates neurological deficits in hyperglycemic stroke mice by reducing microglial pro-inflammatory transition.
Why the study?
Abrupt hyperglycemic reperfusion after thrombectomy harms efficacy, and whether verapamil exerts direct neuroprotective effects and alleviates glucose toxicity post-thrombectomy was unknown.
Does intra-arterial verapamil improve functional outcomes and reduce glucose toxicity in a preclinical model of hyperglycemic stroke?
Does intra-arterial verapamil improve functional outcomes and reduce glucose toxicity in a preclinical model of hyperglycemic stroke?
Intra-arterial verapamil attenuates neurological deficits and reduces microglial pro-inflammatory transition in a preclinical model of hyperglycemic stroke, suggesting a potential neuroprotective strategy for patients undergoing thrombectomy.
Answers are grounded in this paper and cite their sources.
May warrant investigation as adjunctive neuroprotection in hyperglycemic stroke; leaves open translation to thrombectomy patients.
The abrupt hyperglycemic reperfusion following thrombectomy has been shown to harm the efficacy of the intervention in stroke patients with large vessel occlusion. Studies of ours and others have shown thioredoxin-interacting protein (TXNIP) is critically involved in hyperglycemic stroke injury. We recently found verapamil ameliorates cerebrovascular toxicity of tissue plasminogen activators in hyperglycemic stroke. The present study aims to answer if verapamil exerts direct neuroprotective effects and alleviates glucose toxicity following thrombectomy in a preclinical model of hyperglycemic stroke. Primary cortical neural (PCN) cultures were exposed to hyperglycemic reperfusion following oxygen-glucose deprivation (OGD), with or without verapamil treatment. In a mouse model of intraluminal stroke, animals were subjected to 4 h middle cerebral artery occlusion (MCAO) and intravenous glucose infusion. Glucose infusion lasted one more hour at reperfusion, along with intra-arterial (i.a.) verapamil infusion. Animals were subjected to sensorimotor function tests and histological analysis of microglial phenotype at 72 h post-stroke. According to our findings, glucose concentrations (2.5-20 mM) directly correlated with TXNIP expression in OGD-exposed PCN cultures. Verapamil (100 nM) effectively improved PCN cell neurite growth and reduced TXNIP expression as well as interaction with NOD-like receptor pyrin domain-containing-3 (NLRP3) inflammasome, as determined by immunoblotting and immunoprecipitation. In our mouse model of extended hyperglycemic MCAO, i.a. verapamil (0.5 mg/kg) could attenuate neurological deficits induced by hyperglycemic stroke. This was associated with reduced microglial pro-inflammatory transition. This finding encourages pertinent studies in hyperglycemic patients undergoing thrombectomy where the robust reperfusion may exacerbate glucose toxicity.
No takes yet. Share an insight, caveat, or question.
Nasoohi et al. (2023) studied Hyperglycemic stroke. Intra-arterial verapamil vs. Vehicle/Control (Hyperglycemic stroke without verapamil) was evaluated on Neurological deficits (Bederson's score and modified neurological severity score) at 72 h post-stroke (p=<0.05). Intra-arterial verapamil attenuated neurological deficits and reduced microglial pro-inflammatory transition in a mouse model of extended hyperglycemic stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: